Figure 3

SSR240612 treatment improved spatial learning and memory in APP mice after 5 (A) and 10 weeks (B) of treatment. In the Morris water maze, APP mice (▲) displayed impaired learning in the hidden-platform testing (left), and memory deficit in the probe trial (platform removed) performed on day 9 (right) compared to both non-treated WT (●) and treated WT (○) controls. SSR240612 partly rescued these deficits in treated APP mice (Δ) that did not statistically differ from WT control groups. SSR240612 had no effect in WT. APP mice did not feature motor or visual deficits as shown by their ability to reach the visible platform as effectively as WT by day 3. Error bars represent SEM. *P <0.05; **, ††P <0.01; ***, †††P <0.001. Two-way ANOVA followed by Newman-Keuls post hoc test (†: APP vs. WT, *: APP vs. APP treated). N = 10 to 15/group. APP, amyloid precursor protein; WT, wild-type.